To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
About the study
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III clinical trial. It will be conducted at selected investigational sites globally. The study is comprised of 2 parts.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Male or non-pregnant female adults, ≥18 years old of age at the time of randomization;
- Participants should have at least one of COVID-19 risk factor;
- Participants should have at least 2 COVID-19 related symptoms;
- Has symptoms consistent with COVID-19 as determined by the investigator with onset ≤7 days before randomization;
- First positive SARS-CoV-2 viral infection tested (PCR or antigen-based diagnostic tests) in samples collected ≤3 days prior to start of the infusion;
- Participants are currently not hospitalized;
- Participant (or legal authorized representative) has signed the ICF before any clinical activity related to SCTA01 trial;
- Women with childbearing potential must agree to use effective contraceptive methods during the study period;
- Patient should not participate in other clinical studies related to COVID-19 or SARS-CoV-2 infection.
EXCLUSION CRITERIA
Exclusion Criteria:
- Have known allergies to any of the components used in the formulation of the SCTA01/placebo;
- Participants with a history of severe anaphylaxis, such as severe anaphylactic reaction, urticaria, and angioedema;
- Have SpO2 ≤ 93% on room air at sea level or PaO2/FiO2 < 300, respiratory rate ≥30 per minute, heart rate ≥125 per minute (FDA);
- Require mechanical ventilation or anticipated impending need for mechanical ventilation;
- Suspected or proven serious bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking part in this study;
- Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study;
- Have any co-morbidity requiring surgery within <29 days, or that is considered life threatening within 29 days;
- Have a history of previous SARS-CoV-2 infection;
- Received convalescent plasma, COVID-19 vaccine, or anti-SARS-CoV-2 spike(S) protein targeted therapy;
- Have participated in a clinical study involving an investigational intervention within past 30 days or 5-half lives of investigational product, whichever is longer;
- Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing;
- Pregnant or lactating women;
- Anticipated hospitalization or transfer to another medical site which is not a study site within 72 hours;
- Participants unable to follow the protocol during the study;
- Participants deemed inappropriate for enrollment by the investigator due to other factors.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
COVID-19,SARS-CoV-2
Age (in years)
18+
Phase
Phase 2/Phase 3
Participants needed
690
Est. Completion Date
Mar 1, 2022
Treatment type
Interventional
Sponsor
Sinocelltech Ltd.
ClinicalTrials.gov identifier
NCT04709328
Study number
SCTA01-A301
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?